Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 19/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12974289 | 0.92 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2718259 | 0.90 | PIK3CD (0.87) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3784558 | 0.90 | PIK3CD (0.87) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL8480736 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL13063170 | 0.84 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2718946 | 0.83 | PIK3CD (0.83) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3777667 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL3782630 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL2717996 | 0.83 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CBPIK3CACYP2D6 | |
| SCHEMBL12974178 | 0.83 | PIK3CD (0.82) | PIK3CDPIK3CGPIK3CBPIK3CACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CG 53/4885PIK3CB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.